about
Novel oral anticoagulants and the 73rd anniversary of historical warfarinThe new oral anticoagulants and the future of haemostasis laboratory testingSpecial considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillationWarfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case.Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol.The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patientsPractical aspects of the oral new anticoagulants.Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa.Dabigatran and kidney disease: a bad combination.Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.
P2860
Q26771544-0656C0C7-A6F3-4BA5-95A0-244D32EEFCFFQ27022461-BECF7796-385E-4600-933A-606703E9D93EQ28072542-8D27774C-E19B-4655-BC01-149F0821724CQ31131437-99C26777-BDB3-4118-80D8-62A4641EFDACQ35746798-CF93AF4E-BD40-48D9-B989-8D8B4C024372Q36101603-00B8EB28-F3C0-45D7-9EC1-73A9CED0A613Q36258652-80B5B2B0-2DD9-4AC2-95D8-F0A79726C8ABQ37014482-C09E3F31-6118-46FD-8FD5-BCA4C3D895FFQ37889781-FFA2C485-9198-43DB-9E43-4E87BB7ED11EQ37903926-7BBA7ED1-BF25-416C-9F41-5D70243438DBQ38122675-E8025A91-14C0-46EB-B9B8-02682F1AC42DQ38164313-1B1C4C2B-736D-452B-A9AB-D28563720906
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Warfarin versus new agents: interpreting the data.
@ast
Warfarin versus new agents: interpreting the data.
@en
type
label
Warfarin versus new agents: interpreting the data.
@ast
Warfarin versus new agents: interpreting the data.
@en
prefLabel
Warfarin versus new agents: interpreting the data.
@ast
Warfarin versus new agents: interpreting the data.
@en
P1476
Warfarin versus new agents: interpreting the data.
@en
P2093
Jack Ansell
P304
P356
10.1182/ASHEDUCATION-2010.1.221
P577
2010-01-01T00:00:00Z